AMENDMENTS TO THE SPECIFICATION

IN THE SPECIFICATION:

Before line 1 of the specification, please insert the following new paragraph:

This application is a Divisional of co-pending Application No. 09/942,709, filed on August 31, 2001, which is a Continuation of 08/749,031 (now abandoned), which is a Continuation of 08/236,013 (now abandoned) filed May 2, 1994, which is a Continuation of 07/976,457 (now abandoned) filed November 13, 1992, the entire contents of which are hereby incorporated by reference and for which priority is claimed under 35 U.S.C. § 120; and this application claims priority of Application No. 3-326961 filed in Japan on November 14, 1991 under 35 U.S.C. § 119.

The paragraph beginning on page 8, line 26 and ending on page 9, line 5 has been amended as follows:

--Boc-Lys(Cl-Z)-Val-Leu-Arg(Tos)-His(Tos)-PAM-Resin (SEQ ID NO: 3), wherein protected amino acids were purchased from Applied Biosystems, was synthesized from Boc-His(Tos)-PAM-Resin (Applied Biosystems) (0.25mmol) by an amino acid synthesizer such as SHIONOGI SRL-02 according to the usual solid phase method. This was

deprotected with HF/anisole. The crude peptide thus obtained was subjected to reversed phase chromatography (column: Wako Pure Chemical RQ-2, 24 x 360 mm) with linear gradient of 0-50% CH_3CN/0.1% CF_3COOH for purification to give 59 mg of the desired peptide. --

The paragraph beginning on page 20, line 3 has been amended as follows:

--Because hBNP has no Tyr residue to be labeled, Tyr^0-hBNP, i.e., hBNP having an additional Tyr residue at the N-terminus, was synthesized. Namely, Boc-Tyr(Br-Z)-Ser(Bzl)-Pro-~~Lsy~~ Lys(Cl-Z)-Met-Val-Gln-Gly-Ser(Bzl)-Gly-Cys(4-CH_3OBzl)-Phe-Gly-Arg(Tos)-Lys(Cl-Z)-Met-Asp(OcHex)-Arg-Ile-Ser(Bzl)-Ser(Bzl)-Ser(Bzl)-Ser(Bzl)-Gly-Leu-Gly-Cys(4-CH_3OBzl)-Lys(Cl-Z)-Val-Leu-Arg(Tos)-Arg(Tos)-His(Bom)-PAM-resin (SEQ ID NO:1) was synthesized from 0.45 mmol of Boc-His(Bom)-PAM-resin (NOVA Biochem AG) according to the usual solid phase method using an amino acid synthesizer, Applied Biosystems 430A. A half amount of the obtained peptide was deprotected with HF/p-crezole/dimethylsulfide and diluted with distilled water. After adjusting the pH to 9 with aqueous ammonium, the mixture was agitated at room temperature for 24 h to introduce a S-S bridge. Thus obtained crude peptide was subjected to reversed phase chromatography (column: YMC S-50 120A ODS AM-type, 30 x 200 mm)

with a linear gradient of 0-40 % CH_3CN/0.1 % CF_3COOH, then to HPLC fractionation (column: μ-bondasphere 15C18 300A, 30 x 300 mm (Waters)) with a linear gradient of 12-22 % CH_3 CN/0.1 % CF_3COOH, and further purified by means of a column of YMC 342-5 S-5 120A ODS (20 x 150 mm) with a solvent of 19.5 % CH_3CN/ 0.1 % CF_3COOH to give 3.9 mg of the desired peptide.--

SEQUENCE LISTING

Enclosed herewith in full compliance with 37 C.F.R. §§1.821-1.825 is a copy of the Sequence Listing that was filed in the parent application Serial No. 09/942,709 on February 28, 2002. A copy of this Sequence Listing was also submitted in computer readable form (CRF) in the application Serial No. 09/942,709. The CRF of this Sequence Listing consists of a disk copy of the Sequence Listing which is in full compliance with 37 C.F.R. §§1.821-1.825. The disk copy of this Sequence Listing, file "0032-0262.app", which may be found in the file of application Serial No. 09/942,709, is identical to the paper copy submitted herewith, except that it lacks formatting.

Applicants request the use of the compliant computer readable "Sequence Listing" that is already on file for the parent application 09/942,709 in the instant application. The paper copy